InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
4
T+90 hit rate
13%
T+90 mean return
-30.0%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Yorke Justin W, Director. Officer active across 1 company, notably Processa Pharmaceuticals, Inc.. Cumulatively, 19 disclosures have been published. Breakdown: 2 buys · 4 sells. Total volume traded: €87k. Activity tracked since 3 December 2021. The latest transaction was filed on 27 January 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations19 total
12,400 shares@ US$0.797510.2% of flowCommon StockSEC:0000897069-25-000153:0
Ideal exit: 24 Oct 2025 (T+270)
8,000 shares@ US$2.69321.4% of flowCommon StockSEC:0000897069-24-000227:0
Ideal exit: 26 Oct 2024 (T+270)
55,267 shares0Common StockSEC:0000897069-23-001674:0
6,000 shares@ US$0.301.8% of flowCommon StockSEC:0000897069-23-001499:0
6,000 shares@ US$0.301.8% of flowCommon StockSEC:0000897069-23-001462:0
12,000 shares@ US$0.212.6% of flowCommon StockSEC:0000897069-23-001440:0
23,636 sharesCommon StockSEC:0000897069-23-001004:0
1,169 sharesCommon StockSEC:0001567619-23-000303:0
18,208 sharesCommon StockSEC:0001567619-23-000329:0
4,393 sharesCommon StockSEC:0001567619-22-015312:0
4,393 sharesCommon StockSEC:0001567619-22-008006:0
1,854 shares@ US$3.300.083% mcap9.4% of flowCommon StockSEC:0001567619-22-002079:0
1,854 shares@ US$3.305.8% of flowCommon StockSEC:0001567619-22-002079
5,500 shares@ US$4.83620.36% mcap40.6% of flowCommon StockSEC:0001567619-21-021710:0
5,500 shares@ US$4.836225.3% of flowCommon StockSEC:0001567619-21-021710
1,169 sharesCommon StockSEC:0001567619-21-016570:0
1,169 sharesCommon StockSEC:0001567619-21-016570
1,169 sharesCommon StockSEC:0001567619-21-014756
1,169 sharesCommon StockSEC:0001567619-21-014756:0
19 of 19 declarations
About Yorke Justin W
Justin W. Yorke serves as a Director of Processa Pharmaceuticals, Inc. He provides strategic expertise to the board of directors, contributing to governance and key decision-making for the company. His experience in the pharmaceutical sector is an asset to the organization.
